Live Terminal

VERAXA Biotech Designates Raju Willener as CFO

Share on WhatsApp Telegram
⚡ Instant Key Takeaways (TL;DR)
🎯
Core Development: VERAXA Biotech Designates Raju Willener as CFO
📊
Market & Financial Impact: Live financial intelligence and market filing report on ZeroLive.
💡
Actionable Insight: Monitor price volume action at market open; check key technical support/resistance levels.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025.

Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of the biopharmaceutical development process, the company stated.

"As we advance our proprietary BiTAC technology platform and growing oncology pipeline, Raju's expertise will be highly valuable in optimizing our capital strategy, evaluating strategic opportunities and supporting disciplined execution and long-term shareholder value creation," said Christoph Antz, Ph.D., VERAXA's CEO and co-founder.

The post VERAXA Biotech Designates Raju Willener as CFO appeared first on ExecEdge.

📰
Official Publisher Attribution: This report is aggregated from Yahoo Finance. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.
Read Original Full Coverage on Yahoo Finance ↗
Link copied to clipboard! ✅